Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Panelists discuss how remibrutinib demonstrated rapid and sustained efficacy in the REMIX-1 and -2 trials through significant improvements in disease activity scores (UAS7, ISS7, HSS7) starting at week 1 and maintained through 52 weeks, with nearly half of patients achieving complete symptom resolution (UAS7 = 0) by week 52, while maintaining a favorable safety profile throughout the study period.

Overview of Remibrutinib Phase 3 Clinical Trials in CSU

Metz shared highlights from 2 presentations he gave on barzolvolimab’s efficacy at the AAAAI/WAO Joint Congress.

Achieving Chronic Spontaneous and Inducible Urticaria Control With Barzolvolimab, with Martin Metz, MD

Panelists discuss how pharmacological Bruton tyrosine kinase (BTK) inhibition with agents like remibrutinib appears safer than genetic BTK deficiency (X-linked agammaglobulinemia [XLA]), as clinical studies show the drug doesn't significantly impact immunoglobulin levels or infection rates in patients with chronic spontaneous urticaria (CSU), unlike the severe immunodeficiency seen in XLA.

Differentiating BTK Inhibition From Genetic BTK Deficiency

Panelists discuss how newer Bruton tyrosine kinase (BTK) inhibitors being developed for chronic spontaneous urticaria (CSU), particularly remibrutinib (in phase 3 trials) and rilzabrutinib (in phase 2), are designed to be more selective than earlier oncology-focused BTK inhibitors, potentially reducing off-target effects like bleeding, cardiovascular complications, and GI issues.

Overview of BTK Inhibitors in Development for CSU Treatment

By week 52, remibrutinib and placebo-to-remibrutinib groups had similar levels of urticaria control.

Add-on Remibrutinib Quickly Improves Urticaria Control in CSU

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors offer a novel upstream approach, in contrast to current treatments that work downstream by either blocking released mediators (antihistamines), neutralizing circulating IgE (omalizumab), or broadly suppressing immune responses (immunosuppressants).

How BTK Inhibitors Differ From Current CSU Treatment Approaches

Panelists discuss how Bruton tyrosine kinase (BTK) inhibition could effectively treat both autoallergic and autoimmune chronic spontaneous urticaria (CSU).

BTK Inhibition as a Strategy for CSU Treatment

At week 12, a higher proportion of participants on rilzabrutinib 1200mg a day (60.9%) achieved AAS7 scores of 0 than placebo-treated participants (30.8%). 

Rilzabrutinib Yields Responses in Angioedema in People With CS Urticaria

Bernstein discussed recent and upcoming research and management of angioedema in patients with urticaria.

Understanding Angioedema in Urticaria, with Jonathan Bernstein, MD

Around half of participants had insufficient vitamin D levels.

Solar Urticaria More Prevalent in Women, UV and Visible Light Both Common Triggers

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.